Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity
Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity
复制标题
DOI：
10.1002/jbmr.551
复制
发表时间：
2012-01-01
影响因子：
6.2
通讯作者：
Egli, Andreas
中科院分区：
文献类型：
--
作者：
Bischoff-Ferrari, Heike Annette;Dawson-Hughes, Bess;Egli, Andreas
测试25（OH）D3（HyD）与维生素D3相比对血清25-羟基维生素D水平（25（OH）D）、下肢功能、血压和先天免疫标志物的影响。20名平均25（OH）D水平为13.2 +/- 3.9ng/mL（平均值+/- SD）、平均年龄为61.5 +/- 7.2岁的健康绝经后妇女以双盲方式随机接受20 μ g HyD或20 μ g（800 IU）维生素D3/天。我们在4个月内的14次就诊中测量了25（OH）D血清水平、血压和7种先天免疫标志物（嗜酸细胞活化趋化因子、白细胞介素[IL]-8、IL-12、干扰素γ诱导蛋白10 kDa [IP-10]、单核细胞趋化蛋白-1 [MCP-1]、巨噬细胞炎性蛋白β [MIP-1 β]和活化后调节、正常T细胞表达和分泌[RANTES]）。在基线和4个月时，评估下肢功能测试组合（膝关节伸肌和屈肌力量，定时起身和行走，重复坐立）。所有分析均根据基线测量值、年龄和体重指数进行校正。HyD组的平均25（OH）D水平升高至69.5 ng/mL。这种增长是立即和持续的。平均25（OH）D水平增加到31.0ng/mL，维生素D3组缓慢增加。与维生素D3相比，服用HyD的女性维持或改善下肢功能的几率增加2.8倍（比值比[OR]=2.79; 95%置信区间[CI]，1.186.58），收缩压降低5.7 mmHg（p =0.0002）。两种类型的维生素D都有助于降低先天免疫的七种标志物中的五种，对于eotaxin，IL-12，MCP-1和MIP-1 β，HyD更明显。在任何时间点均无高钙血症病例。每天20微克（20 μ g）的HyD导致所有参与者的25（OH）D血清水平安全，立即和持续增加，这可以解释其对下肢功能，收缩压和先天性免疫反应的显着益处。(C)2012年美国骨与矿物质研究学会
To test the effect of 25(OH)D3 (HyD) compared to vitamin D3 on serum 25-hydroxyvitamin D levels (25(OH)D), lower extremity function, blood pressure, and markers of innate immunity. Twenty healthy postmenopausal women with an average 25(OH)D level of 13.2 +/- 3.9ng/mL (mean +/- SD) and a mean age of 61.5 +/- 7.2 years were randomized to either 20 mu g of HyD or 20 mu g (800 IU) of vitamin D3 per day in a double-blind manner. We measured on 14 visits over 4 months, 25(OH)D serum levels, blood pressure, and seven markers of innate immunity (eotaxin, interleukin [IL]-8, IL-12, interferon gamma-induced protein 10 kDa [IP-10], monocyte chemotactic protein-1 [MCP-1], macrophage inflammatory protein beta [MIP-1 beta], and Regulated upon Activation, Normal T-cell Expressed, and Secreted [RANTES]). At baseline and at 4 months, a test battery for lower extremity function (knee extensor and flexor strength, timed up and go, repeated sit-to-stand) was assessed. All analyses were adjusted for baseline measurement, age, and body mass index. Mean 25(OH)D levels increased to 69.5 ng/mL in the HyD group. This rise was immediate and sustained. Mean 25(OH)D levels increased to 31.0ng/mL with a slow increase in the vitamin D3 group. Women on HyD compared with vitamin D3 had a 2.8-fold increased odds of maintained or improved lower extremity function (odds ratio [OR]=2.79; 95% confidence interval [CI], 1.186.58), and a 5.7-mmHg decrease in systolic blood pressure (p =0.0002). Both types of vitamin D contributed to a decrease in five out of seven markers of innate immunity, significantly more pronounced with HyD for eotaxin, IL-12, MCP-1, and MIP-1 beta. There were no cases of hypercalcemia at any time point. Twenty micrograms (20 mu g) of HyD per day resulted in a safe, immediate, and sustained increase in 25(OH)D serum levels in all participants, which may explain its significant benefit on lower extremity function, systolic blood pressure, and innate immune response compared with vitamin D3. (C) 2012 American Society for Bone and Mineral Research